Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Harris, P.A., Faucher, N., George, N., Eidam, P.M., King, B.W., White, G.V., Anderson, N.A., Bandyopadhyay, D., Beal, A.M., Beneton, V., Berger, S.B., Campobasso, N., Campos, S., Capriotti, C.A., Cox, J.A., Daugan, A., Donche, F., Fouchet, M.H., Finger, J.N., Geddes, B., Gough, P.J., Grondin, P., Hoffman, B.L., Hoffman, S.J., Hutchinson, S.E., Jeong, J.U., Jigorel, E., Lamoureux, P., Leister, L.K., Lich, J.D., Mahajan, M.K., Meslamani, J., Mosley, J.E., Nagilla, R., Nassau, P.M., Ng, S.L., Ouellette, M.T., Pasikanti, K.K., Potvain, F., Reilly, M.A., Rivera, E.J., Sautet, S., Schaeffer, M.C., Sehon, C.A., Sun, H., Thorpe, J.H., Totoritis, R.D., Ward, P., Wellaway, N., Wisnoski, D.D., Woolven, J.M., Bertin, J., Marquis, R.W.
J.Med.Chem.